This study highlights the potential of DNA-based systems to minimize off-target effects through rational design. The programmability of DNA enables precise tuning of OligoPROTAC structures, including the length, sequence, and binding affinities of the various components. This level of customization can further enhance therapeutic specificity. The implications of this work extend beyond improving the safety and efficacy of PROTAC therapies. The integration of DNA nanotechnology into protein degradation strategies opens the door to a broader class of "smart" therapeutics capable of adaptive responses to biological cues. For example, OligoPROTACs could be engineered to respond to disease-specific biomarkers, ensuring that therapeutic activity is restricted to pathological conditions. Furthermore, the modularity of DNA nanotechnology provides opportunities for multiplexed targeting, enabling the simultaneous degradation of multiple proteins in a coordinated manner.